The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study
Abstract Background Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) an...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-022-02772-y |
| _version_ | 1797984077168508928 |
|---|---|
| author | Kexin Feng Shuangtao Zhao Qingyao Shang Guangdong Qiao Jiaxiang Liu Chenxuan Yang Ya Wei Yalun Li Fei Ren Lixue Xuan Xiang Wang Xin Wang |
| author_facet | Kexin Feng Shuangtao Zhao Qingyao Shang Guangdong Qiao Jiaxiang Liu Chenxuan Yang Ya Wei Yalun Li Fei Ren Lixue Xuan Xiang Wang Xin Wang |
| author_sort | Kexin Feng |
| collection | DOAJ |
| description | Abstract Background Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI) were introduced. The present study aimed to evaluate the prognostic value of IPI and the other IPIs in patients with PBL in a Chinese population. Methods We performed a multicenter retrospective study of 71 patients with PBL from 3 institutions in China. The Kaplan–Meier method and log-rank tests were used for the survival analysis. Cox regression analysis was performed to evaluate the prognostic factors. Subgroup analysis was performed to assess the prognostic significance of IPI scores, R-IPI scores, and NCCN-IPI scores. Results The median follow-up was 4.7 years (0.7–21.8 years). The 5-year progression-free survival (PFS) and overall survival (OS) rates were 90.2% and 96.3%. In the multivariate analysis, only IPI scores and radiotherapy were significantly associated with OS and PFS (P < 0.05). Applying the R-IPI in our patient cohort indicates a significant difference in PFS between the two groups of R-IPI (P = 0.034) but not for OS (P = 0.072). And the NCCN-IPI was prognostic for OS (P = 0.025) but not for PFS (P = 0.066). Subgroup analyses of IPI showed that survival analysis of IPI scores for the PFS and OS of patients using rituximab were not significantly different (P > 0.05). Conclusions Our study confirms the prognostic value of IPI in patients with PBL, but the predictive value of IPI proved to be relatively low with the addition of the rituximab. The R-IPI and NCCN-IPI can accurately assess the high and low-risk groups of PBL patients but were insufficient to evaluate the intermediate risk group. |
| first_indexed | 2024-04-11T06:56:50Z |
| format | Article |
| id | doaj.art-7f2b648d9b8347708b3ead9a9b32cc9d |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-04-11T06:56:50Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-7f2b648d9b8347708b3ead9a9b32cc9d2022-12-22T04:39:01ZengBMCCancer Cell International1475-28672022-11-0122111610.1186/s12935-022-02772-yThe prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective studyKexin Feng0Shuangtao Zhao1Qingyao Shang2Guangdong Qiao3Jiaxiang Liu4Chenxuan Yang5Ya Wei6Yalun Li7Fei Ren8Lixue Xuan9Xiang Wang10Xin Wang11Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Thoracic Surgery, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical UniversityDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgery, Yantai Yuhuangding HospitalDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgery, An Yang Tumor HospitalDepartment of Breast Surgery, Yantai Yuhuangding HospitalDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI) were introduced. The present study aimed to evaluate the prognostic value of IPI and the other IPIs in patients with PBL in a Chinese population. Methods We performed a multicenter retrospective study of 71 patients with PBL from 3 institutions in China. The Kaplan–Meier method and log-rank tests were used for the survival analysis. Cox regression analysis was performed to evaluate the prognostic factors. Subgroup analysis was performed to assess the prognostic significance of IPI scores, R-IPI scores, and NCCN-IPI scores. Results The median follow-up was 4.7 years (0.7–21.8 years). The 5-year progression-free survival (PFS) and overall survival (OS) rates were 90.2% and 96.3%. In the multivariate analysis, only IPI scores and radiotherapy were significantly associated with OS and PFS (P < 0.05). Applying the R-IPI in our patient cohort indicates a significant difference in PFS between the two groups of R-IPI (P = 0.034) but not for OS (P = 0.072). And the NCCN-IPI was prognostic for OS (P = 0.025) but not for PFS (P = 0.066). Subgroup analyses of IPI showed that survival analysis of IPI scores for the PFS and OS of patients using rituximab were not significantly different (P > 0.05). Conclusions Our study confirms the prognostic value of IPI in patients with PBL, but the predictive value of IPI proved to be relatively low with the addition of the rituximab. The R-IPI and NCCN-IPI can accurately assess the high and low-risk groups of PBL patients but were insufficient to evaluate the intermediate risk group.https://doi.org/10.1186/s12935-022-02772-yPrimary breast lymphoma (PBL)IPIR-IPINCCN-IPIRituximabBreast cancer |
| spellingShingle | Kexin Feng Shuangtao Zhao Qingyao Shang Guangdong Qiao Jiaxiang Liu Chenxuan Yang Ya Wei Yalun Li Fei Ren Lixue Xuan Xiang Wang Xin Wang The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study Cancer Cell International Primary breast lymphoma (PBL) IPI R-IPI NCCN-IPI Rituximab Breast cancer |
| title | The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study |
| title_full | The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study |
| title_fullStr | The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study |
| title_full_unstemmed | The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study |
| title_short | The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study |
| title_sort | prognostic value of ipi in patients with primary breast lymphoma a multicenter retrospective study |
| topic | Primary breast lymphoma (PBL) IPI R-IPI NCCN-IPI Rituximab Breast cancer |
| url | https://doi.org/10.1186/s12935-022-02772-y |
| work_keys_str_mv | AT kexinfeng theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT shuangtaozhao theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT qingyaoshang theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT guangdongqiao theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT jiaxiangliu theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT chenxuanyang theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT yawei theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT yalunli theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT feiren theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT lixuexuan theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT xiangwang theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT xinwang theprognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT kexinfeng prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT shuangtaozhao prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT qingyaoshang prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT guangdongqiao prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT jiaxiangliu prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT chenxuanyang prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT yawei prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT yalunli prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT feiren prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT lixuexuan prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT xiangwang prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy AT xinwang prognosticvalueofipiinpatientswithprimarybreastlymphomaamulticenterretrospectivestudy |